Biotechnology Value Fund — Full Portfolio
16 tracked investments · listed companies and verified rows first
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesCasdin Capital+2 more
Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.
BiotechHealthtech
Co-investorsForesite CapitalNextech InvestOrbiMed
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalJanus Henderson InvestorsREDMILESalvia
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin S Eisenfrats(Executive Officer, Director, Promoter)Kevin Eisenfrats(Co-Founder and CEO)John Herr(Co-Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)
Co-investorsMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture CapitalCleo Capital+14 more
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForbionLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
BiotechSeattle, US
Dr. Mitchell H Gold(Executive Officer, Director)Mitchell Gold(Executive Chairman and Chief Executive Officer)Michael Kornacker(Executive Officer, Director)Ryan Swanson(Executive Officer, Director)David Miller(Executive Officer, Director)James Paul Rickey(Senior Vice President and Chief Financial Officer)
Co-investorsDecheng CapitalFrazier Life Sciences
BiotechBoulder, US
Nicholas Traggis(Executive Officer, Director)
BoardKyle Lefkoff(Director)inDavid Snitman(Director)William S. Marshall(Director)John Orwin(Director)
Co-investorsBoulder Ventures
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesOmega FundsTenmileAbingworth
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsMirae Asset Venture InvestmentPfizer VenturesPolaris PartnersTaiho Ventures, LLC
BiotechBoston, US
Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)
BoardOtello Stampacchia(Director)in
Co-investorsAtlas VentureForesite CapitalOmega FundsOrbiMedRTW Investments L.P.
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundCatalio Capital Management+2 more
Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.
BiotechHealthtech
Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)
Co-investorsBain Capital Life SciencesThird Rock VenturesGV (Google Ventures)
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)
BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)
Co-investorsLongitude CapitalSofinnova VenturesVida VenturesFrazier Life Sciences
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen HorowitzVida Venturesabrdn plcForesite CapitalHillhouse InvestmentOmega Funds+1 more
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoCasdin CapitalFonds de solidarité FTQGV (Google Ventures)+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.